查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867515

肾上腺脑白质营养不良症治疗：全球市场份额和排名、总收入和需求预测（2025-2031年）

Adrenoleukodystrophy Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 82 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球肾上腺脑白质营养不良症治疗市场预计在 2024 年达到 2.53 亿美元，预计到 2031 年将达到 5.91 亿美元，2025 年至 2031 年的复合年增长率为 10.9%。

肾上腺脑白质营养不良症 (ALD) 的治疗方法旨在预防、延缓或逆转由 ABCD1 基因突变导致中枢神经系统和肾上腺中极长链脂肪酸 (VLCFA) 积累引起的神经退化和内分泌症状。治疗治疗方法包括旨在调节脂肪酸代谢和缓解症状的代谢干预；造血干细胞移植 (HSCT) 相关疗法，如果早期应用，可以阻止脑部疾病的进展；以及近年来出现的单剂量基因替代疗法，该疗法可纠正自体细胞中的潜在基因缺陷。临床策略因表型而异，包括儿童脑型 ALD (CALD)、肾上腺髓鞘形成性神经病变 (AMN) 和肾上腺功能不全，每种表型的作用机制、给药途径和调控路径都各不相同。基因疗法为早期活动性肾上腺脑白质营养不良症（ALD）且缺乏匹配供体的男性患者提供了一种创新的单剂量治疗选择，但同时也需要长期的安全监测以及复杂的商业化和报销问题。总而言之，从传统的支持疗法到先进的细胞和基因疗法，肾上腺脑白质营养不良症的治疗正在重塑这一罕见疾病领域的临床实践、支付方评估以及研发重点。

在精准医疗的成熟和监管机构对罕见疾病创新优先发展的推动下，肾上腺脑白质营养不良症（ALD）治疗领域正处于一个转折点。单剂量基因替代疗法的监管加速审批和有条件核准，为缺乏匹配供体的早期活动性肾上腺脑白质营养不良症患者开闢了一条商业性可行性的治疗途径，从而改变了临床诊疗流程，并激励支付方和医疗服务提供方协商长期、以疗效为导向的合同。公共卫生措施以及新生儿和标靶筛检计画的扩展，提高了早期检出率，并扩大了可进行治疗性介入和高价值干预的患者群体。建构整合研发、生产和专业治疗中心的协作交付模式的公司，能够获得差异化的市场进入和持续的临床合作。

创新风险和商业化复杂性是主要的阻碍因素。儘管基因疗法已展现出令人信服的疗效，但长期安全性问题（尤其是与载体整合相关的骨髓恶性肿瘤）需要长期监测，这增加了监管标籤和医保覆盖范围的复杂性，并影响了其推广应用的速度。针对罕见疾病、高成本疗法的差异化报销给跨境产品推广带来了挑战。自体细胞产品的生产和物流需要大量的资金和营运能力。患者群体本身规模较小且临床表现多样，限制了快速扩大规模和投资回报。公司申报文件和监管沟通凸显了申办者需要同时应对临床、监管和卫生经济方面的压力。

下游需求正朝着「筛检-治疗-管理」一体化生态系转变。新生儿筛检筛检率和特定疾病的筛检率不断提高，推动了对早期根治性治疗（造血干细胞移植或基因治疗）的需求；同时，患者家属和临床医生也需要可靠的长期安全性、生活品质和功能性结局数据，从而推动了对追踪服务和支持性护理的需求。支付者越来越接受与长期疗效挂钩的创新报销机制，迫使申办方制定上市后证据产生策略和可扩展的追踪基础设施。因此，采购模式将从单一产品采购演变为结合诊断、治疗和长期疗效管理的捆绑式服务。

本报告旨在按地区/国家、类型和应用对全球肾上腺脑白质营养不良治疗市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以收益为准，以2024年为基准年，对肾上腺脑白质营养不良症治疗药物市场规模、估计值和预测进行了阐述，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定肾上腺脑白质营养不良症治疗药物的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Bluebird Bio
  • NeuroVia
  • Orpheris
  • Minoryx
  • MedDay Pharmaceuticals
  • Rocket Pharmaceuticals
  • Lysogene
  • Sangamo Therapeutics

按类型分類的细分市场

  • 荷尔蒙补充疗法
  • 移植
  • 其他的

应用领域

  • 儿童脑血管酒精性肝病
  • 肾上腺髓鞘形成性神经病变（AMN）
  • 仅爱迪生氏症
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Adrenoleukodystrophy Drugs was estimated to be worth US$ 253 million in 2024 and is forecast to a readjusted size of US$ 591 million by 2031 with a CAGR of 10.9% during the forecast period 2025-2031.

Adrenoleukodystrophy (ALD) drugs are therapeutic solutions designed to prevent, slow, or reverse the neurodegenerative and endocrine manifestations caused by mutations in the ABCD1 gene, which lead to accumulation of very-long-chain fatty acids (VLCFAs) in the central nervous system and adrenal glands. The therapeutic landscape includes metabolic interventions (aimed at modulating fatty-acid metabolism and symptomatic support), hematopoietic stem cell transplant (HSCT)-related approaches that can arrest cerebral disease progression when performed early, and the more recent single-administration gene-replacement therapies that correct the underlying genetic defect in autologous cells. Clinical strategies differ markedly by phenotype - childhood cerebral ALD (CALD), adrenomyeloneuropathy (AMN), or adrenal insufficiency - and thus vary in mechanism of action, delivery modality, and regulatory pathway. Gene therapy introduces a potentially transformative one-time option for boys with early, active CALD who lack matched donors, while also imposing long-term safety monitoring and complex commercialization and reimbursement considerations. Overall, ALD drugs now span from conventional supportive regimens to advanced cell and gene therapeutics, reshaping clinical practice, payer evaluation, and R&D priorities in this ultra-rare disease area.

The ALD therapeutic space is experiencing an inflection point driven by the maturation of precision medicine and regulatory prioritization of rare-disease innovation. Regulatory acceleration and conditional approvals for one-time gene-replacement therapies have created a commercially viable pathway for treating boys with early, active CALD who lack matched donors-transforming clinical algorithms and motivating payers and providers to negotiate long-term outcome-based arrangements. Public health initiatives and expanded newborn or targeted screening programs are improving early detection rates, which in turn expand the addressable population for curative and high-value interventions. Companies that integrate R&D, manufacturing and Centers of Excellence into a coordinated delivery model can secure differentiated market access and durable clinical partnerships.

Innovation risk and commercialization complexity are prominent restraints. While gene therapies demonstrate compelling efficacy, long-term safety concerns-particularly vector integration-related hematologic malignancies-require extended monitoring and complicate regulatory labeling and payer coverage, thereby affecting adoption speed. Cross-border launches face heterogeneous reimbursement frameworks for ultra-rare, high-cost therapies; manufacturing and logistics for autologous cell-based products demand significant capital and operational capabilities. The patient population is inherently small and clinically heterogeneous, constraining rapid scale-up and return on investment. Company filings and regulatory communiques highlight that sponsors must manage clinical, regulatory and health-economic pressures in parallel.

Downstream demand is shifting toward an integrated "screen-treat-manage" ecosystem. Rising newborn and targeted screening rates will increase demand for early definitive interventions (HSCT or gene therapy), while families and clinicians will require robust long-term safety, quality-of-life, and functional-outcome data-driving growth in follow-up services and supportive care. Payers are increasingly receptive to innovative reimbursement constructs tied to long-term outcomes, prompting sponsors to design post-marketing evidence-generation strategies and scalable follow-up infrastructures. Consequently, procurement will evolve from single-product purchases toward bundled offerings that combine diagnostics, therapeutic delivery, and longitudinal outcomes management.

This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Adrenoleukodystrophy Drugs by region & country, by Type, and by Application.

The Adrenoleukodystrophy Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Drugs.

Market Segmentation

By Company

  • Bluebird Bio
  • NeuroVia
  • Orpheris
  • Minoryx
  • MedDay Pharmaceuticals
  • Rocket Pharmaceuticals
  • Lysogene
  • Sangamo Therapeutics

Segment by Type

  • Hormone Replacement
  • Transplant
  • Others

Segment by Application

  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Adrenoleukodystrophy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Adrenoleukodystrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Adrenoleukodystrophy Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Adrenoleukodystrophy Drugs Product Introduction
  • 1.2 Global Adrenoleukodystrophy Drugs Market Size Forecast (2020-2031)
  • 1.3 Adrenoleukodystrophy Drugs Market Trends & Drivers
    • 1.3.1 Adrenoleukodystrophy Drugs Industry Trends
    • 1.3.2 Adrenoleukodystrophy Drugs Market Drivers & Opportunity
    • 1.3.3 Adrenoleukodystrophy Drugs Market Challenges
    • 1.3.4 Adrenoleukodystrophy Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Adrenoleukodystrophy Drugs Players Revenue Ranking (2024)
  • 2.2 Global Adrenoleukodystrophy Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Adrenoleukodystrophy Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Adrenoleukodystrophy Drugs
  • 2.6 Adrenoleukodystrophy Drugs Market Competitive Analysis
    • 2.6.1 Adrenoleukodystrophy Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Adrenoleukodystrophy Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Hormone Replacement
    • 3.1.2 Transplant
    • 3.1.3 Others
  • 3.2 Global Adrenoleukodystrophy Drugs Sales Value by Type
    • 3.2.1 Global Adrenoleukodystrophy Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Adrenoleukodystrophy Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Adrenoleukodystrophy Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Childhood Cerebral ALD
    • 4.1.2 Adrenomyeloneuropathy (AMN)
    • 4.1.3 Addison-only
    • 4.1.4 Others
  • 4.2 Global Adrenoleukodystrophy Drugs Sales Value by Application
    • 4.2.1 Global Adrenoleukodystrophy Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Adrenoleukodystrophy Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global Adrenoleukodystrophy Drugs Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Adrenoleukodystrophy Drugs Sales Value by Region
    • 5.1.1 Global Adrenoleukodystrophy Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Adrenoleukodystrophy Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Adrenoleukodystrophy Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Adrenoleukodystrophy Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.2.2 North America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.3.2 Europe Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Adrenoleukodystrophy Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.5.2 South America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.3.2 United States Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.5.2 China Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.9.2 India Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Bluebird Bio
    • 7.1.1 Bluebird Bio Profile
    • 7.1.2 Bluebird Bio Main Business
    • 7.1.3 Bluebird Bio Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.1.4 Bluebird Bio Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Bluebird Bio Recent Developments
  • 7.2 NeuroVia
    • 7.2.1 NeuroVia Profile
    • 7.2.2 NeuroVia Main Business
    • 7.2.3 NeuroVia Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.2.4 NeuroVia Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 NeuroVia Recent Developments
  • 7.3 Orpheris
    • 7.3.1 Orpheris Profile
    • 7.3.2 Orpheris Main Business
    • 7.3.3 Orpheris Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.3.4 Orpheris Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Orpheris Recent Developments
  • 7.4 Minoryx
    • 7.4.1 Minoryx Profile
    • 7.4.2 Minoryx Main Business
    • 7.4.3 Minoryx Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.4.4 Minoryx Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Minoryx Recent Developments
  • 7.5 MedDay Pharmaceuticals
    • 7.5.1 MedDay Pharmaceuticals Profile
    • 7.5.2 MedDay Pharmaceuticals Main Business
    • 7.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 MedDay Pharmaceuticals Recent Developments
  • 7.6 Rocket Pharmaceuticals
    • 7.6.1 Rocket Pharmaceuticals Profile
    • 7.6.2 Rocket Pharmaceuticals Main Business
    • 7.6.3 Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.6.4 Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Rocket Pharmaceuticals Recent Developments
  • 7.7 Lysogene
    • 7.7.1 Lysogene Profile
    • 7.7.2 Lysogene Main Business
    • 7.7.3 Lysogene Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.7.4 Lysogene Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Lysogene Recent Developments
  • 7.8 Sangamo Therapeutics
    • 7.8.1 Sangamo Therapeutics Profile
    • 7.8.2 Sangamo Therapeutics Main Business
    • 7.8.3 Sangamo Therapeutics Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.8.4 Sangamo Therapeutics Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Sangamo Therapeutics Recent Developments

8 Industry Chain Analysis

  • 8.1 Adrenoleukodystrophy Drugs Industrial Chain
  • 8.2 Adrenoleukodystrophy Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Adrenoleukodystrophy Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Adrenoleukodystrophy Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Adrenoleukodystrophy Drugs Market Trends
  • Table 2. Adrenoleukodystrophy Drugs Market Drivers & Opportunity
  • Table 3. Adrenoleukodystrophy Drugs Market Challenges
  • Table 4. Adrenoleukodystrophy Drugs Market Restraints
  • Table 5. Global Adrenoleukodystrophy Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Adrenoleukodystrophy Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Adrenoleukodystrophy Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Adrenoleukodystrophy Drugs
  • Table 10. Global Adrenoleukodystrophy Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Adrenoleukodystrophy Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Adrenoleukodystrophy Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Adrenoleukodystrophy Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Adrenoleukodystrophy Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Adrenoleukodystrophy Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Adrenoleukodystrophy Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Adrenoleukodystrophy Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Adrenoleukodystrophy Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Adrenoleukodystrophy Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Adrenoleukodystrophy Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Adrenoleukodystrophy Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Bluebird Bio Basic Information List
  • Table 32. Bluebird Bio Description and Business Overview
  • Table 33. Bluebird Bio Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Bluebird Bio (2020-2025)
  • Table 35. Bluebird Bio Recent Developments
  • Table 36. NeuroVia Basic Information List
  • Table 37. NeuroVia Description and Business Overview
  • Table 38. NeuroVia Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of NeuroVia (2020-2025)
  • Table 40. NeuroVia Recent Developments
  • Table 41. Orpheris Basic Information List
  • Table 42. Orpheris Description and Business Overview
  • Table 43. Orpheris Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Orpheris (2020-2025)
  • Table 45. Orpheris Recent Developments
  • Table 46. Minoryx Basic Information List
  • Table 47. Minoryx Description and Business Overview
  • Table 48. Minoryx Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Minoryx (2020-2025)
  • Table 50. Minoryx Recent Developments
  • Table 51. MedDay Pharmaceuticals Basic Information List
  • Table 52. MedDay Pharmaceuticals Description and Business Overview
  • Table 53. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of MedDay Pharmaceuticals (2020-2025)
  • Table 55. MedDay Pharmaceuticals Recent Developments
  • Table 56. Rocket Pharmaceuticals Basic Information List
  • Table 57. Rocket Pharmaceuticals Description and Business Overview
  • Table 58. Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Rocket Pharmaceuticals (2020-2025)
  • Table 60. Rocket Pharmaceuticals Recent Developments
  • Table 61. Lysogene Basic Information List
  • Table 62. Lysogene Description and Business Overview
  • Table 63. Lysogene Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Lysogene (2020-2025)
  • Table 65. Lysogene Recent Developments
  • Table 66. Sangamo Therapeutics Basic Information List
  • Table 67. Sangamo Therapeutics Description and Business Overview
  • Table 68. Sangamo Therapeutics Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Sangamo Therapeutics (2020-2025)
  • Table 70. Sangamo Therapeutics Recent Developments
  • Table 71. Key Raw Materials Lists
  • Table 72. Raw Materials Key Suppliers Lists
  • Table 73. Adrenoleukodystrophy Drugs Downstream Customers
  • Table 74. Adrenoleukodystrophy Drugs Distributors List
  • Table 75. Research Programs/Design for This Report
  • Table 76. Key Data Information from Secondary Sources
  • Table 77. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Adrenoleukodystrophy Drugs Product Picture
  • Figure 2. Global Adrenoleukodystrophy Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Adrenoleukodystrophy Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Adrenoleukodystrophy Drugs Report Years Considered
  • Figure 5. Global Adrenoleukodystrophy Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Adrenoleukodystrophy Drugs Revenue in 2024
  • Figure 7. Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Hormone Replacement Picture
  • Figure 9. Transplant Picture
  • Figure 10. Others Picture
  • Figure 11. Global Adrenoleukodystrophy Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Adrenoleukodystrophy Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Childhood Cerebral ALD
  • Figure 14. Product Picture of Adrenomyeloneuropathy (AMN)
  • Figure 15. Product Picture of Addison-only
  • Figure 16. Product Picture of Others
  • Figure 17. Global Adrenoleukodystrophy Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Adrenoleukodystrophy Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Adrenoleukodystrophy Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Adrenoleukodystrophy Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value (%), (2020-2031)
  • Figure 30. United States Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Adrenoleukodystrophy Drugs Industrial Chain
  • Figure 52. Adrenoleukodystrophy Drugs Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed